Update on the Management of Acanthamoeba Keratitis

Purpose or Review In this article, we review the latest diagnostic modalities and management of acanthamoeba keratitis Recent Findings The incidence as well as severity of acanthamoeba keratitis is increasing, making this a challenging disease to treat, especially in patients who have a delay in diagnosis or severe disease at presentation. Newer tools such as voriconazole, miltefosine, and collagen crosslinking may be needed for infection control. Complications such as persistent infection, severe thinning, or perforation may necessitate surgical intervention. Summary While traditional therapies such as polyhexamethylene biguanide and chlorhexidine remain mainstays of therapy, unresponsive acanthamoeba keratitis may benefit from topical or oral voriconazole, oral miltefosine, or collagen crosslinking. Despite these options, management of these patients remains a challenge.